111In-anti-γH2AX-Tat

111In-anti-γH2AX-Tat is a radiolabeled immunoconjugate developed by researchers at the University of Oxford for the non-invasive imaging of DNA double-strand breaks (DSBs) and the DNA damage response (DDR). The agent consists of a monoclonal antibody targeting phosphorylated histone H2AX (γH2AX), a key marker of DSBs, conjugated to the cell-penetrating peptide Tat (which contains a nuclear localization sequence to facilitate nuclear translocation) and labeled with the gamma-emitting radioisotope Indium-111 (111In). It is designed for single-photon emission computed tomography (SPECT) imaging to monitor early therapeutic responses to DNA-damaging therapies, such as external beam radiotherapy, chemotherapy, or molecular radiotherapies like 177Lu-DOTATATE, and can also act as a radiosensitizer to amplify treatment-related DNA damage.

Other names

111In-DTPA-anti-γH2AX-Tat111In-anti-gH2AX-TAT111In-anti-γH2AX-TAT